Legal Analysis: What Australian Courts Have Actually Ruled on Puberty Blockers for Children

When Equality Australia welcomed a Supreme Court judgment on puberty blockers in August 2024, it was reacting to a very specific family story. A twelve-year-old girl known only as CD had been attending the Royal Children's Hospital Gender Service in Melbourne since she was eight. Her doctors recommended puberty blockers because the physical changes of early puberty were causing her intense distress. Her mother, AB, agreed. Her father had been out of the picture since she was a baby. The hospital, unsure whether one parent's consent was enough, asked the Supreme Court of Victoria for clarity.

Justice Melinda Richards gave it. She found that the mother's consent was sufficient. Stage 1 treatment, the puberty blockers, did not need to be treated as some special category of medical decision that automatically required a judge's say-so. It should be handled the same way as consent for childhood vaccinations, surgery for a broken bone, or chemotherapy. Because the father was long absent and there were no court orders changing the usual rules of parental responsibility, the mother could decide. The hospital's application was dismissed. No court order was needed.

That decision did not come out of nowhere. For years Australian families and doctors had been navigating a patchwork of older rulings. The High Court of Australia has never handed down a judgment that directly addresses puberty blockers for gender dysphoria. Its most important contribution remains the 1992 case known as Marion's Case, which set the outer limits of what parents can authorise for children who cannot yet decide for themselves. Certain irreversible or non-therapeutic procedures, the High Court said, sit outside ordinary parental authority and need court approval. Everything else has been left to the Family Court (now the Federal Circuit and Family Court) and, occasionally, state Supreme Courts.

In 2013 the Full Court of the Family Court decided in Re Jamie that parents could consent to puberty blockers without a court order if everyone agreed. Four years later, in Re Kelvin, the same court said the same thing about cross-sex hormones once a young person was mature enough to understand the decision (Gillick competence) and there was no dispute. Then in 2020 Re Imogen introduced a note of caution: if parents, the child or the doctors disagree about diagnosis, capacity or the treatment itself, the matter must go to court. Some later decisions read Re Imogen as requiring both parents' affirmative consent even when one parent had been absent for years. That reading created exactly the uncertainty the Victorian hospital faced with CD. Justice Richards pushed back, treating those comments as not binding and restoring the more straightforward position that one present, caring parent can give valid consent when the other is simply not there.

So where does that leave a child under twelve today? There is no national legal ban tied to chronological age. Clinical guidelines usually link the start of blockers to the earliest physical signs of puberty (Tanner stage 2), which can arrive before a child's twelfth birthday. The legal test remains the same: is there agreement between the treating doctors and the parent or parents who hold responsibility? If yes, treatment can proceed without a court application. If there is genuine disagreement, the Federal Circuit and Family Court becomes the place where the decision is made, guided always by the child's best interests.

That national picture is not uniform. Queensland and the Northern Territory have restricted new prescriptions of puberty blockers and gender-affirming hormones for under-18s in the public system. In Queensland the restriction survived a court challenge that focused on process rather than the medical merits, and it has since been extended while the state waits for longer-term evidence from a major UK trial. Private prescribing is not covered by those public-system rules. Elsewhere the older common-law and Family Court framework still applies.

For the families in the middle of this, the legal language can feel distant from the daily reality of a distressed child and anxious parents. Courts keep repeating that these decisions are not about ideology; they are about whether the treatment is, on the evidence before the judge, in this particular child's best interests. The Victorian ruling in CD's case tried to reduce one source of unnecessary stress: the fear that an absent parent's silence could force a family into costly and drawn-out litigation even when the present parent and the medical team were aligned.

The story is still unfolding. A national review of clinical guidelines is under way. Individual cases continue to reach the courts when parents disagree. But the core legal position for children under twelve remains the one shaped by the Family Court precedents and clarified, for the situation of an absent parent, by the Victorian Supreme Court in 2024. The High Court has not spoken on this specific treatment. State Supreme Courts and the specialist family courts have carried the work so far, case by case, family by family.

Case Law

Re CD [2024] VSC 456